REGULATORY

• CEFP Kicks Off Discussions on Economic and Fiscal Policy Blueprint for 2017
  March 31, 2017

• Members of New Counterfeits Panel Call for Eliminating Cash-and-Carry Dealers
  March 31, 2017

• Clinical Research Bill Likely to Clear Diet Early April
  March 31, 2017

• MHLW Approves Ninlaro, Intuniv, Other Drugs
  March 31, 2017

• MHLW to Set up New Council to Discuss Safety Measures for Pharmacotherapy in the Elderly
  March 31, 2017

• Drug Price Survey Sheets to Be Distributed with No Prefectural Govts In-Between: Chuikyo
  March 30, 2017

• AMED Racks Up 1st Out-Licensing Cases in Drug Discovery Support Initiative
  March 30, 2017

• Chuikyo Gives Ex-Post Nod to Opdivo’s Optimal Use Guidelines for Head-and-Neck Cancer
  March 30, 2017

• CDISC-Based Electronic Submissions for 19 Products Since October: PMDA
  March 29, 2017

• MHLW Seeks Cooperation for Sovaldi’s PMS for Genotype 3-6 Use
  March 28, 2017

• Promotion Plan for Cancer Genomics Due Out This Summer
  March 28, 2017

• MHLW Issues Optimal Use Guidelines for Opdivo Following Approval of Add’l Indication for Head and Neck Cancer
  March 28, 2017

• MHLW Orders Label Revisions for Lamictal, Zione
  March 27, 2017

• Orphan Designation Granted for Olaparib, 3 Other Drugs
  March 27, 2017

• Cabinet OKs PMDA’s Review Fee Raise from April 1
  March 27, 2017

• MHLW OKs Sovaldi for Genotypes 3-6, Opdivo for Head and Neck Cancer
  March 27, 2017

• MHLW Poised to Review System Designs to Prevent Counterfeits: Minister
  March 24, 2017

• No Extra Fees Will Be Charged for Add’l Survey Items for MID-NET’s PMS Use: MHLW Working Group
  March 23, 2017

• Clinical Research Bill Passes Lower House
  March 23, 2017

• MHLW Orders Label Revisions for 44 APIs in Sleep/Anxiolytic/Epilepsy Agents
  March 21, 2017

ページ

• « 先頭
• ‹ Prev
• …
• 249
• 250
• 251
• 252
• 253
• 254
• 255
• 256
• 257
• …
• Next ›
• 最終 »